# ClinicalTrials.gov record NCT04263415

> PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04263415-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04263415-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04263415-semaglutide-v1.json
- Content SHA-256: `8076002e2f7a586ac81430add93a92cb875b9698ae1a5e8d1f61a8e50a9d2eff`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04263415 ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

## Sources

<a id="source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0"></a>
- **ClinicalTrials.gov record NCT04263415 · retained source version 2023-09-08:3fa8d01bf7c0f53b7678f33bdd217ff76b881e295eb0dceb2ee20b7cb0f6f977** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04263415) (`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04263415." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04263415-semaglutide-v1.json SHA-256: 8076002e2f7a586ac81430add93a92cb875b9698ae1a5e8d1f61a8e50a9d2eff.